Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7492.091 | 1.0286 | 1.0392 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7492.091 | 0.9688 | 0.9568 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7492.091 | 1.0405 | 1.0554 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7492.091 | 1.0608 | 1.0828 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7492.091 | 0.9782 | 0.9700 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7492.091 | 0.9695 | 0.9578 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7492.091 | 0.8055 | 0.7236 | 1.4539 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7493.091 | 1.0374 | 1.0689 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7493.091 | 1.0050 | 1.0093 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7493.091 | 1.0461 | 1.0847 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7493.091 | 1.0850 | 1.1560 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7493.091 | 1.0382 | 1.0702 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7493.091 | 1.0655 | 1.1204 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7493.091 | 1.1077 | 1.1976 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7493.091 | 1.0687 | 1.1262 | 1.0859 | |
| MCF7 | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7493.091 | 0.8825 | 0.7826 | 1.0859 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000171 | uM | 7494.09 | 0.9070 | 0.8275 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.000853 | uM | 7494.09 | 0.9476 | 0.9030 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.00427 | uM | 7494.09 | 0.9328 | 0.8754 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.0213 | uM | 7494.09 | 0.9649 | 0.9350 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.107 | uM | 7494.09 | 0.8840 | 0.7846 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 0.533 | uM | 7494.09 | 0.9828 | 0.9682 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 2.67 | uM | 7494.09 | 0.9617 | 0.9291 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 13.3 | uM | 7494.09 | 0.8886 | 0.7932 | 1.0823 | |
| MDA-MB-134-VI | HR+ | Luminal | Erlotinib | EGFR | ErbB | 66.7 | uM | 7494.09 | 0.7776 | 0.5852 | 1.0823 |